Marcello Disertori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/30304/publications.pdf

Version: 2024-02-01

1307594 1125743 15 487 7 13 citations g-index h-index papers 15 15 15 995 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Myocardial Fibrosis Assessment by LGE IsÂa Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic andÂNonischemic LV Dysfunction. JACC: Cardiovascular Imaging, 2016, 9, 1046-1055.	5.3	248
2	Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends in Cardiovascular Medicine, 2017, 27, 363-372.	4.9	87
3	The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy. Europace, 2013, 15, 1693-1701.	1.7	41
4	Heart Rate Turbulence Is a Powerful Predictor of Cardiac Death and Ventricular Arrhythmias in Postmyocardial Infarction and Heart Failure Patients. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	37
5	Primary Prevention of Sudden Arrhythmic Death in Dilated Cardiomyopathy. JACC: Heart Failure, 2017, 5, 39-43.	4.1	26
6	Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view. Journal of Cardiovascular Medicine, 2016, 17, 245-255.	1.5	16
7	Declining clinical benefit of ICD in heart failure patients: Temporal trend of mortality outcomes from randomized controlled trials. Journal of Cardiology, 2020, 75, 148-154.	1.9	11
8	Ventricular tachycardia-inducibility predicts arrhythmic events in post-myocardial infarction patients with low ejection fraction. A systematic review and meta-analysis. IJC Heart and Vasculature, 2018, 20, 7-13.	1,1	7
9	Implantable Cardioverter-Defibrillator in Dilated Cardiomyopathy after the DANISH-Trial Lesson. A Poly-Parametric Risk Evaluation Is Needed to Improve the Selection of Patients. Frontiers in Physiology, 2017, 8, 873.	2.8	6
10	Is the clinical benefit of primary prevention implantable cardioverter-defibrillator overestimated? The role of sudden cardiac death to total mortality ratio. European Heart Journal, 2020, 41, 4525-4526.	2.2	4
11	Heart failure patients unresponsive to implantable cardioverterâ€defibrillator therapy: a neglected problem. European Journal of Heart Failure, 2019, 21, 1507-1509.	7.1	2
12	Atrial fibrillation and NPPA gene p.S64R mutation. Journal of Cardiovascular Medicine, 2016, 17, 177-180.	1.5	1
13	The postâ€DANISH era in clinical cardiology: Need of a better selection of patients for implantable cardioverterâ€defibrillator in dilated cardiomyopathy. Journal of Cardiovascular Electrophysiology, 2017, 28, E7.	1.7	1
14	Author's reply: "Declining clinical benefit of ICD in heart failure patients― Journal of Cardiology, 2020, 75, 584-585.	1.9	0
15	The paradox of implantable cardioverter-defibrillator: When guidelines may play against care improvement. American Heart Journal, 2021, 233, 149-150.	2.7	O